Lu-Ping Li1, JoAnn Carbray1,
Maria Papadopulou-Rosenzweig2, Richard Solomon3,
Pottumarthi V. Prasad1
1Radiology, Northshore University
Healthsystem, Evanston, IL, United States; 2Radiation Medicine,
Northshore University Healthsystem, Evanston, IL, United States; 3Nephrology,
University of Vermont, Burlington, Burlington, VT, United States
Radiocontrast
nephropathy (RCN) is the 3rd common cause of in-hospital mortality in
patients with pre-existing kidney insufficiency. Although low- and
iso-osmolal radiocontrast are in general believed to be safer than older
ionic and high-osmolal agents, the issue remains controversial. Renal hypoxia
plays a role in the pathophysiology of RCN and BOLD MRI was previously shown to be useful
in monitoring the changes in intra-renal oxygenation with iothalamate, a 1st
generation ionic high osmolality agent.
Here, we report our preliminary findings using iodixanol, a 3rd
generation nonionic iso-osmolality agent, that suggest similar trends as reported
earlier with iothalamate.